The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

A silent health crisis may be developing inside your body without any obvious warning signs. Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease ...

PathAI, a global leader in AI-powered pathology, today announced that the U.S. Food and Drug Administration (FDA) has qualified AIM-MASH AI Assist through the Drug Development Tool (DDT) Biomarker ...

At the Liver Meeting sponsored by the American Association for the Study of Liver Diseases, investigators presented new ...

A new study brings researchers closer to better understanding the pathology of the fatty liver disease MASH, which stands for metabolic dysfunction-associated steatohepatitis. MASH is a consequence of ...

I was first told that I was at higher risk for fatty liver disease in 2005. I had never heard the term before. My primary care provider didn't seem too concerned about excess fat building up in my ...

The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help doctors assess a ...

MASH patients exhibit a higher spleen-to-liver stiffness ratio than ALD patients, indicating a presinusoidal component in portal hypertension. The study found that MASH patients have larger spleen ...

Roughly 1 in 3 adults has metabolic dysfunction–associated steatotic liver disease, or MASLD. A doctor outlines how to detect and slow the condition early.

Excessive sugar consumption can overwhelm your liver, leading to fat accumulation, inflammation, insulin resistance, and ...